Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

GenMark Diagnostics to Present at the William Blair 33rd Annual Growth Stock Conference

GenMark Diagnostics to Present at the William Blair 33rd Annual Growth Stock Conference

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the William Blair 33rd Annual Growth Stock Conference to be held at the Four Seasons Hotel in Chicago, IL, on Wednesday, June 12, 2013. Hany Massarany, President and Chief Executive Officer, will present at 4:00 p.m. Central Time (2:00 p.m. Pacific Time).

A live webcast and audio archive of the presentation will be available at http://ir.genmarkdx.com/events.cfm. A replay of the webcast will be available on the company's website for approximately 90 days.

ABOUT GENMARK

GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor® XT-8 system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. GenMark currently markets four tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test, Respiratory Virus Panel, Thrombophilia Risk Test, and Warfarin Sensitivity Test. A number of other tests, including HCV Genotyping, 2C19 Genotyping, and 3A4/3A5 Genotyping are available for research use only. For more information, visit www.genmarkdx.com.

<div class="copyright"> Copyright Business Wire 2013 </div>